BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Business

  TC Biopharm and the Nipro Corporation Announce Strategic Programme Co-Developing a Novel Gamma-Delta Car-T Product to Treat Cancer

  TCB intends to use this novel platform to develop new CA-based immunotherapies, with the aim of treating a broad range of cancers and major viral disease

  February 7, 2018

   · 

  3 min read
• Drug Development

  Synairgen Phase II Clinical Trial Commences Dosing in Patients With COPD

  Synairgen today announces that the first patients have been dosed in the Company’s Phase II trial of inhaled SNG001 in patients with chronic obstructive pulmonary disease.

  February 7, 2018

   · 

  2 min read
• Business

  Nuvasive Announces Conference Call and Webcast of Fourth Quarter and Full Year 2017 Results

  NuVasive will hold a conference call on Monday, February 26, 2018, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the fourth quarter and full year 2017.

  February 7, 2018

   · 

  2 min read
• Business

  Stellar Biotechnologies Reports First Quarter 2018 Financial Results

  Stellar Chief Financial Officer Kathi Niffenegger said that during the first quarter, the company completed multiple engineering lots under its optimization initiative and continued to prioritize research and development.

  February 7, 2018

   · 

  12 min read
• Business

  Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record Revenues, Strong Earnings

  Lannett today reported financial results for its fiscal 2018 second quarter ended December 31, 2017.

  February 7, 2018

   · 

  65 min read
• 

  Business

  Cardiovascular Systems Names a New CFO, Effective Immediately

  Points succeeds Larry Betterley as CFO and will report to Scott Ward, Chairman, President and CEO.

  February 7, 2018

   · 

  4 min read
• Genetown

  Sage Therapeutics Announces Proposed Public Offering of $575 Million of its Common Stock

  Sage Therapeutics today announced that it has commenced an underwritten public offering of $575.0 million of its common stock.

  February 7, 2018

   · 

  4 min read
• Pharm Country

  Cold Spring Harbor Laboratory Release: Autism Genetics Study Calls Attention to Impaired Motor Skills, General Cognitive Impairment

  A new study of genetic factors involved causing autism spectrum disorders draws fresh attention to the impact these illnesses have on motor skills, and more broadly on cognitive function.

  February 7, 2018

   · 

  2 min read
• Policy

  Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

  Therapix announced today that it has held a pre-Investigational New Drug communication with the FDA to discuss the regulatory pathway for the development of THX-110 for the treatment of Tourette Syndrome.

  February 7, 2018

   · 

  6 min read
• Sinovac Provides Update on Going Private Transaction

  Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement.

  February 7, 2018

   · 

  4 min read